iRhythm Data Challenges Short-Term Holter Monitoring Standards
Event summary
- iRhythm presented data at HRS 2026 showing short-term Holter monitoring misses 26% of AF recurrences post-ablation and 60% of clinically significant arrhythmias in pregnancy.
- Retrospective analyses involved 11,051 post-ablation patients and 486 pregnant women using Zio ambulatory ECG devices.
- Findings suggest current 24–48-hour monitoring standards may lead to misclassification of up to 1 in 4 AF recurrence cases.
- Zio devices demonstrated 99.2% analyzable time, supporting extended monitoring for accurate arrhythmia detection.
The big picture
iRhythm’s data challenges the long-standing reliance on short-duration Holter monitoring, aligning with broader industry trends toward continuous cardiac monitoring. The findings could reshape post-ablation care and pregnancy management, where accurate arrhythmia detection is critical for stroke prevention and maternal health outcomes. With over 12 million patient reports analyzed since its inception, iRhythm is positioning itself as a leader in evidence-based cardiac diagnostics.
What we're watching
- Clinical Adoption
- How quickly will guidelines shift from short-term to extended monitoring post-ablation and during pregnancy?
- Regulatory Impact
- Whether the FDA or other regulators will mandate longer monitoring periods for arrhythmia detection.
- Competitive Response
- The pace at which competitors like Medtronic or Abbott introduce extended-monitoring solutions to challenge iRhythm's lead.